Who We Are

Founded in 2016, TrueBinding Inc. is a pioneering clinical-stage biotherapeutic company at the forefront of creating groundbreaking molecules to address a wide spectrum of challenging medical conditions. We focus on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS, as well as stroke, metabolic disorders, oncology, and other areas with significant unmet medical needs, dedicated to advancing therapies that hold the potential to transform patient outcomes.

TrueBinding's success is owed to our cutting-edge TrueBinding™ platform, a proprietary technology that has proven its mettle in drug discovery and development. Leveraging this powerful platform, we have made significant strides, having already discovered and validated over 6 novel drug targets. Through the development of potentially game-changing monoclonal antibody therapeutics, we are positioned as a major player in the biopharmaceutical industry, bringing hope to patients and healthcare providers alike.

In addition to groundbreaking drug discovery and development endeavors, TrueBinding also offers contract development and manufacturing services that provide considerable advantages to its partners and clients. Leveraging their extensive expertise and state-of-the-art facilities, we enable biopharmaceutical companies to accelerate the development and production of monoclonal antibodies with utmost efficiency.